(Q50664664)

English

Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.

scientific article published on 22 June 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24965823

Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. (English)

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24965823

1 reference

based on heuristic

inferred from title

multicenter clinical trial

1 reference

based on heuristic

inferred from title

nephrotic syndrome

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24965823

author name string

Kazumoto Iijima

1

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24965823

Mayumi Sako

2

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24965823

Kandai Nozu

3

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24965823

Nao Tuchida

5

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24965823

Koichi Kamei

6

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24965823

Kenichiro Miura

7

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24965823

Kunihiko Aya

8

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24965823

Koichi Nakanishi

9

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24965823

Yoshiyuki Ohtomo

10

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24965823

Shori Takahashi

11

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24965823

Ryojiro Tanaka

12

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24965823

Hiroshi Kaito

13

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24965823

Hidefumi Nakamura

14

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24965823

Kenji Ishikura

15

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24965823

Shuichi Ito

16

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24965823

Yasuo Ohashi

17

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24965823

Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group

18

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24965823

language of work or name

0 references

publication date

22 June 2014

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24965823

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24965823

384

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24965823

1273-1281

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24965823

9950

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24965823

Nephrotic syndrome in childhood.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: superiority of response to corticosteroid therapy over histopathologic patterns.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Interventions for idiopathic steroid-resistant nephrotic syndrome in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment with microemulsified cyclosporine in children with frequently relapsing nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Two-year cyclosporin treatment in children with steroid-dependent nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Two-year follow-up of a prospective clinical trial of cyclosporine for frequently relapsing nephrotic syndrome in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab therapy for steroid-dependent minimal change nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Does rituximab increase the incidence of infectious complications? A narrative review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Fatal pulmonary fibrosis after rituximab administration.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Titrating Rituximab to Circulating B Cells to Optimize Lymphocytolytic Therapy in Idiopathic Membranous Nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathogenesis of lipoid nephrosis: a disorder of T-cell function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Altered B-cell signaling in lupus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

B cells in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

T regulatory cell function in idiopathic minimal lesion nephrotic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Minimal change nephrotic syndrome associated with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of T regulatory cells attenuates idiopathic nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960541-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(14)60541-9

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24965823

1 reference

Europe PubMed Central

17 March 2018

http://europepmc.org/abstract/MED/24965823

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50664664&oldid=1561068837"